The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate

#1760

Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.

Aim(s): To support phase 3 data per EMA request.

Materials and methods: In this ongoing, open-label, phase 4 trial (NCT01525550), pts received SU 37.5mg once daily. Eligibility criteria were similar to the phase 3 study. The primary endpoint was investigator-assessed PFS per RECIST 1.0. Secondary endpoints included, PFS per Choi Criteria, overall survival (OS), objective response rate (ORR) and adverse events (AEs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Raymond E, Kulke M, Qin S, Yu X, Schenker M,

Keywords: pNET, survival, sunitinib,